Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

CAPE-COVID, 2020
 
NCT02517489
RCTHydrocortisoneplaceboCOVID-19 severe or criticallylow
76/73 inconclusive
  • inconclusive 29 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
COALITION II (Furtado), 2020
 
NCT04321278
RCTHydrocortisonehydroxychloroquineCOVID-19 severe or criticallysome concern
214/183 inconclusive
    CODEX (Tomazini), 2020
     
    NCT04327401
    RCTdexamethasonestandard of careCOVID-19 severe or criticallysome concern
    151/148 inconclusive
      Edalatifard, 2020
       
      IRCT20200404046947N1
      RCTmethylprednisolonestandard of careCOVID-19 severe or criticallyhigh
      34/34 conclusif
      • demonstrated 71 % decrease in deaths (PE) but with a low degree of certainty due to high risk of bias
      REMAP-CAP, fixed 7-day course, 2020
       
      NCT02735707
      RCTHydrocortisonestandard of careCOVID-19 severe or criticallysome concern
      143/108 inconclusive
        REMAP-CAP, shock-dependent course, 2020
         
        NCT02735707
        RCTcorticosteroidsstandard of careCOVID-19 severe or criticallysome concern
        152/108 inconclusive
          Jianfeng, 2020 OBScorticosteroidsstandard of careCOVID-19 severe or criticallyserious
          -/- safety concern
          • statistically significant 1.8-fold increase in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
          • statistically significant 2.0-fold increase in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
          Raef, 2020 OBScorticosteroidsstandard of careCOVID-19 severe or criticallycritical
          -/- suggested
          • suggested 55 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
          Lu, 2020 OBScorticosteroidscontrolCOVID-19 severe or criticallyserious
          151/93 inconclusive

            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).